Annual report pursuant to Section 13 and 15(d)

Segment Disclosures

v3.22.0.1
Segment Disclosures
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Segment Disclosures Segment Disclosures
The Company has two reportable segments: EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The reportable segments are each managed separately because they serve distinct markets.

The Company evaluates performance and allocates resources based on segment gross profit margin. The Company does not consider net assets as a segment measure and, accordingly, assets are not allocated.

Segment reporting information is as follows:
EksoHealth EksoWorks Total
Year ended December 31, 2021
Revenue $ 9,750  $ 1,496  $ 11,246 
Cost of revenue 3,746  751  4,497 
Gross profit $ 6,004  $ 745  $ 6,749 
Year ended December 31, 2020
Revenue $ 8,066  $ 816  $ 8,882 
Cost of revenue 3,219  593  3,812 
Gross profit $ 4,847  $ 223  $ 5,070 


Geographically, the regions the Company operates in are the Americas, EMEA, and APAC. Individual countries with revenue greater than 10% of total revenue are disclosed separately from the regional totals. Geographic information for revenue based on location of customers is as follows:
  Year ended December 31,
  2021 2020
United States $ 6,451 $ 5,882
Other 127  79 
Americas 6,578  5,961 
Germany 1,327  884 
Other 2,084  849 
EMEA 3,411  1,733 
APAC 1,257  1,188 
  $ 11,246  $ 8,882